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Objectives To develop a recombinant FIX (rFIX) formulation equivalent to commercially 
available products in terms of cake appearance, residual moisture, proportion of soluble 
aggregates and activity maintenance for 3 months at 4-8°C. 
Results NaCl and low bulking agent/cryoprotectant mass ratio had a negative impact on cake 
quality upon lyophilisation, for a wide range of formulations tested. Particular devised 
formulations were able to maintain rFIX activity after lyophilization with a similar performance 
when compared with the rFIX formulated using the excipients reported for a commercially 
available FIX formulation (Benefix®). The stability study showed that rFIX remained active 
after 3 months when stored at 4°C, though this was not the case with samples stored at 40°C. 
Interestingly, particular formulations were found to show an increase in residual moisture after 3 
months storage, but not above a 3% threshold. All four formulations tested were equivalent to 
the Benefix® formulation in terms of particle size distribution and cake appearance.  
Conclusions Three specific formulations, consisting of surfactant polysorbate-80, sucrose or 
trehalose as cryoprotectant, mannitol or glycine as bulking agent, L-histidine as buffering agent, 
and NaCl added in the reconstitution liquid at a 0.234% (w/v) concentration appear suitable for 
use with a CHO cell derived recombinant FIX.  
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Factor IX (FIX) is a vitamin K-dependent serine protease that is part of the blood coagulation 
cascade and its congenital deficiency causes a bleeding disorder, hemophilia B (Lim et al. 
2010). Treatment of this disease has traditionally involved intra-venous infusion of recombinant 
or human plasma-derived protein concentrates of Factor IX. It is more desirable to use 
recombinant material where control over its manufacture and source is possible, with Factor IX 
usually being expressed in recombinant mammalian cell lines (Amaral et al. 2016) although 
recently its expression in insect cells has also been reported (Vatandoost and Bos, 2016). One 
obstacle in developing efficient therapeutic products containing Factor IX is that the protein is 
sensitive to both chemical and physical degradation. As such, specific formulations and 
preparations must be developed that allow the delivery of a stable and active Factor IX 
preparation.  
Aqueous preparations of FIX often have insufficient shelf-life for delivery and use in the clinic, 
being unstable (Smales et al. 2002) and tending to lose their biological activity, even if stored at 
low temperature (Webb et al. 1997). Thus, freeze-drying to generate lyophilized preparations 
represents a reference process for the manufacturing of high-quality drug products with 
appropriate stability for long-term storage (Lim et al. 2016). The final drug formulation before 
the freeze drying process needs to provide protein stability through all the stresses imposed 
during the freeze drying process, long-term storage and reconstitution (Jameel and Pikal 2010). 
Currently, formulation development is reliant on trial and error knowledge based approaches for 
each target molecule. Therefore, the relationship between protein instability, formulation 
excipients and their concentrations needs to be carefully evaluated for each therapeutic protein. 
The purpose of this work is to report on the relationship between excipient composition and 
Factor IX stability, seeking an alternative formulation which is able to maintain the 
commercially important Factor IX protein stability after lyophilization with appropriate cake 




Materials and Methods 
Production of purified recombinant Factor IX 
The recombinant Factor IX (rFIX) used in this study was produced according to a confidential 
upstream and downstream process developed at the Cell Culture Engineering Laboratory of 
UFRJ (Brazil). In summary, rFIX was produced by CHO (Chinese hamster ovary) cells 
engineered to expression human Factor IX. Cells were cultivated in batch or fed-batch mode in 
stirred-tank bioreactors, and rFIX from the cell culture harvest material was purified using a 2-
step process based on membrane adsorbers, which was adapted from Ribeiro et al. (2013). 
Factor IX protein concentration was assessed by ELISA. 
Preparation, lyophilization and reconstitution of samples  
Throughout this work, samples of each tested formulation (Table 1) were prepared by buffer 
exchange using Amicon® Ultra 10 kDa cut-off membrane (Millipore). Lyophilization of 1 ml 
samples was carried out using a Virtis SP Scientific Advantage Plus lyophilizer instrument and 
the software Synwiz-Plus. The volume used for reconstitution of lyophilized samples was the 
same as starting volume of samples (1 ml). 
Differential scanning calorimetry (DSC) 
To determine the annealing temperature to be used in the lyophilization process, samples 
formulated according to the excipients of two commercial products (Benefix® and Rixubis®) 
were analyzed on a DSC Q 200 (TA instruments) at the cooling/heating rate of 1°C/min, using 
TA Universal Analysis software for data analysis. The excipients added by buffer exchange 
prior to DSC analysis were as follows; (i) based upon that reported by Pfizer 2012, Benefix® - 8 
mM L-histidine, 23 mM sucrose, 0.004% (v/v) polysorbate 80, 208 mM glycine (40 mM NaCl 
added later, by means of the reconstitution solvent); (ii) based upon that reported by Baxalta 
Canada Corp. 2015, Rixubis®, 20 mM L-histidine, 35 mM sucrose, 60 mM NaCl, 0.005% (v/v) 
polysorbate 80, 4 mM calcium chloride, 110 mM mannitol. 
Comparison of lyophilization methods 
Samples were prepared at a protein concentration of 250 µg/ml and analyzed in triplicate for 
each condition. Two different lyophilization methods were compared, using the formulations of 
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commercial products Benefix® and Rixubis®: (i) a method adapted from Ronzi et al. (2003), 
which was proposed for lyophilization of Factors FVIII and IX, and (ii) a method adapted from 
Tang and Pikal (2004), which was proposed for biopharmaceuticals in general. The freeze 
drying programs utilized in this study are described in Table 2 and Table 3. 
Formulation design based on design of experiments (DoE) 
A resolution IV, 2-level fractional factorial design with 8 factors (5 numeric and 3 categorical) 
and 32 centre points (4 replicates for each combination of categorical factors), with a total of 48 
runs, was carried out to investigate concentrations and combinations of different excipient 
classes (cryoprotectant, buffer, salt, bulking agent and surfactant) in the rFIX formulation 
(Supplementary Table 1). Samples were prepared at a protein concentration of 250 µg/ml. The 
responses investigated were cake appearance and rFIX activity after reconstitution with 1 ml 
ultrapure water. 
Freeze drying microscopy (FDM) to further assess the influence of NaCl  
To further investigate the effects of NaCl on the freezing and lyophilization behavior 
(nucleation temperature, collapse and eutectic melting), formulation #6 of the DoE study (no 
NaCl) and its version with 40 mM NaCl were evaluated by freeze drying microscopy (FDM), 
using a Lyostat 2 freeze-drying microscope (Biopharma Technology) coupled to an Olympus 
Plan C 10x/0.25 camera. 
Assessment of rFIX protein stability after lyophilization in different formulations 
Four different formulations were defined and compared to the formulation of commercially 
available Benefix® based upon the initial studies reported here. The components of these four 
formulations A, B C and D can be found in Table: Samples were reconstituted with a solution of 
0.234% (w/v) NaCl solution in ultrapure water, which is the same as the solution supplied with 
Benefix®. Samples were prepared to a protein concentration of  ȝJPO, and each 
formulation was run in duplicate. Vials without excipients, containing only rFIX, were also 
lyophilized to confirm that the excipients were required to protect the protein against the 
stresses imposed by lyophilization process. 
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Factor IX samples were analyzed for residual moisture, cake appearance, the presence 
of aggregates (soluble and insoluble), and biological activity after reconstitution as described 
below. Stability upon lyophilization only was evaluated by reconstituting and analyzing vials 
immediately after lyophilization (time point T0), whereas stability upon storage at 2-8oC and at 
room temperature was analyzed upon reconstitution after 90 days of storage (time point T90). 
For the evaluation of accelerated degradation, lyophilized vials were stored at 40oC for 45 days 
(time point T45) and for 90 days (time point T90), then reconstituted and analyzed. The 
conditions investigated are summarized in Table 4. 
Analytical methods for Factor IX analysis and characterization  
FIX Activity Assay. Factor IX biological activity was determined using a commercial 
chromogenic kit (Biophen Factor IX kit, Hyphen Biomed, France), following the 
PDQXIDFWXUHU¶VLQVWUXFWLRQV 
Karl Fischer Titration. Residual water analysis was determined on a C30 Colorimetric Karl 
Fischer Titrator (Mettler Toledo). An analytical balance (Mettler Toledo) was used to determine 
the mass of analyzed lyophilized samples.  
Soluble aggregate analysis by SEC-HPLC. Samples were analyzed for monomer and soluble 
aggregate amounts using an Agilent Technologies 1200 Series HPLC (Agilent, USA). 100 µl of 
sample was injected onto a TSK gel G3000 SWXL column (5 µm, 7.8 x 300 mm, Tosoh 
Bioscience, USA) was used to separate the monomers from the aggregated species. A gel 
filtration standard (#51-1901, Bio-Rad, USA) was introduced at the start of the runs. The mobile 
phase was 0.1 M anhydrous Na2HPO4, 0.1 M Na2SO4, pH 6.8, with a flow rate of 1 ml/min in 
isocratic mode. 
Dynamic Light Scattering (DLS) for analysis of insoluble aggregates. A Zetasizer Nano 
(Malvern Instruments, USA) was used to determine the size of the particles based on DLS. A 
volume of 60 µl of sample was analyzed using ZEN2112 quartz cuvettes QS 300 nm. The 




Results and Discussion 
A range of formulation excipients and combinations thereof, based upon literature and 
commercial Factor IX preparations, were investigated in order to develop a formulation for a 
recombinant FIX product with comparable stability using standard biochemical techniques. 
However, in order to address this question, it was initially necessary to develop an appropriate 
lyophilization process. 
Definition of the lyophilization annealing temperature based on thermal analysis  
Differential scanning calorimetry (DSC) analysis showed that both rFIX formulations 
investigate initially, containing the excipients of commercial rFIX products Benefix® and 
Rixubis®, ice nucleation temperature of approximately -23°C, ice melting temperature of 0°C 
and eutectic temperature (Teu) of -5°C (Supplementary Figure 1).  
Ice formation during cooling of a protein solution concentrates all solutes which eventually 
changes the solution from a viscous liquid to brittle glass. The temperature of this reversible 
transition for the freeze-concentrated solution is the glass transition temperature (Tg¶) of 
maximally freeze concentrated solution. The collapse temperature (Tcol) is the temperature at 
which the interstitial water in the frozen matrix becomes significantly mobile. Tcol is closely 
related to Tg¶, as Tcol has been considered to be equivalent to Tg¶ of an amorphous system or to 
the eutectic melting temperature of a crystalline system (Wang, 2000). Above (Tcol) the freeze-
dried product loses macroscopic structure and collapses during freeze drying. (Tang and Pikal 
2004).  
For the formulations containing crystalline components, which crystallize completely during 
freezing, the eutectic melting temperature becomes more relevant for the freeze drying process 
to get an elegant cake structure as crystallized excipients undergo melting at Teu (Pansare and 
Patel, 2016). In this case, is preferable that these excipients crystallize completely during 
freezing in order to prevent crystallization during storage. The annealing step is a hold step at a 
temperature above Tg¶ that is frequently necessary to allow efficient crystallization of crystalline 
components, such as mannitol or glycine (Kasper 2011). The eutectic temperature can be used 
to estimate the annealing temperature of the freeze-drying process. However, to maintain a safe 
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margin from Teu, we defined an annealing temperature of -10°C for use in both lyophilization 
methods.  
Comparison of lyophilization methods 
Samples from the two different freeze-drying protocols investigated showed different 
macroscopic structures. The protocol adapted from Tang and Pikal (2004) had an elegant cake 
appearance for Factor IX formulated in the Benefix® formulation, but not for Rixubis® 
formulation. The protocol adapted from Ronzi et al. (2003) did not give a good cake appearance 
for either formulation, presenting a very fragile cake (Figure 1). The method adapted from 
Ronzi was performed using more aggressive conditions with a shorter drying time performed at 
higher temperature and higher pressure. A more traditional approach, in this case yielded a 
better cake appearance, despite the whole process being five times longer. The rFIX activity 
after reconstitution of the material lyophilized according to Tang and Pikal (2004) was 42.2 ± 
7.0 IU/ml for the Benefix® formulation and 35.1 ± 4.6 IU/ml for the Rixubis® formulations. On 
the other hand, the activity of rFIX lyophilized using the method adapted from Ronzi et al. 
(2003) was 34.3 ± 7.8 IU/ml and 38.1 ± 3.8 for the Benefix® and Rixubis® formulations, 
respectively. The biological activity prior to lyophilization was 47.3 ± 4.1 IU/ml, therefore for 
the Tang and Pikal method this represents a recovery of approximately 90% and 74% for 
Benefix® and Rixubis® formulations, respectively. For the Ronzi lyophilization method with 
the same starting material, approximately 73% and 80% of biological activity was recovered for 
the Benefix® and Rixubis® formulations, respectively. There was no significant difference in 
the activity between the two methods, however, even if the product is biologically active, a 
collapsed structure is not acceptable according to the quality standards of the industry (Ronzi et 
al, 2003). Therefore, based on the cake appearance further experiments were undertaken using 
the Tang and Pikal (2004) method and the proposed formulations were compared to the 
Benefix® formulation. 
FIGURE 1 
Investigating the effects of different formulation excipients on Factor IX integrity after 
lyophilization using a design of experiments (DoE) approach 
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The excipients used in the commercial formulations were assumed to be suitable for other CHO 
derived recombinant FIX products though perhaps could be further optimized for this specific 
FIX product using Design of Experiments. These excipients are also among the most commonly 
used for formulation of protein based biopharmaceutical products due their ability to protect 
protein during lyophilization. Disaccharides are used as cryoprotectants to prevent 
conformational changes and degradation during freezing in lyophilized formulations. Sucrose 
and trehalose are commonly used disaccharides (Povey et al 2009), with trehalose sometimes 
preferable as a lyoprotectant for biomolecules due to its higher glass transition temperature. 
Surfactants have been used to maintain the integrity of proteins against surface-induced 
degradations derived from agitation, filtration, filling, freeze-thawing and other stresses that 
may be encountered by the product. Polysorbate 80 (Tween 80) is one of the most common 
surfactants for protein stabilization during freezing, and concentrations from 0.005 to 0.01% 
(v/v) have been used to protect several proteins from freezing denaturation (Wang 2000). 
Specifically, Bush et al. (1998) found that the addition of 0.005% (v/v) polysorbate 80 to a 
recombinant FIX formulation was effective in reducing inactive high molecular weight 
aggregates. Buffering agents are important for maintaining the pH of the solution within an 
acceptable range. From a panel of buffering agents varying from 7 to 7.5 examined by Bush et 
al. (1998), including sodium phosphate, potassium phosphate and Tris, histidine was reported to 
be an excellent buffering agent for minimizing aggregation of lyophilised rFIX during storage at 
30°C. Bulking agents are included in the formulations for various uses, such as to enhance the 
pharmaceutical elegance of the cake and to increase the density of the product (when the drug 
concentration is below 3% w/w) (Jameel and Pikal, 2010). The bulking agents most frequently 
used are glycine and mannitol, they are non-toxic, have high solubility and have been 
successfully used in a variety of protein formulations (Wang 2000). Furthermore, mannitol and 
glycine both crystalize easily, they are easy to reconstitute, and possess high eutectic 
temperatures ranging from approximately í1ƕC to í3ƕC, an attribute very useful in carrying out 
the primary drying at a high product temperature without collapse and loss of elegance (Jameel 
and Pikal 2010). NaCl was included in this study based on Lambert et al. (2007), who proposed 
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Benefix® reformulation using NaCl to increase ionic strength and so to prevent agglutinated red 
blood cells (RBC) in the intravenous tubing (whilst still retaining iso-osmolality). After 
lyophilization and reconstitution of the different DoE samples, analysis of the rFIX activity 
showed no statistically significant differences within the ranges of the different factors 
investigated here. However, a low bulking agent/cryoprotectant mass ratio (w/w) in 
combination with the presence of NaCl had a negative impact on cake appearance. This ratio 
KDV DQ LPSDFWRQ WKH7J¶DQGPD\ WKHUHIRUH LQIOXHQFH WKHSULPDU\GU\LQJ WHPSHUDWXUH Some 
authors recommend that the bulking agent/cryoprotectant mass ratio should be at least 2 (see for 
example Johnson et al. 2002; Liao et al. 2005). A poor cake appearance is characterized by 
shrinkage, cracks and fragility. For the majority of the formulations investigated here with a 
bulking agent to cryoprotectant mass ratio below 2:1, in combination with the lyophilization 
process used, the cake appearance was poor. However, in a number of the formulations 
investigated where NaCl was absence, the cake appearance was considered appropriate (e.g. 
formulations 4, 6 and 12) even when the bulking agent/cryoprotectant mass ratio was low (<2). 
Some formulations with a bulking agent/cryoprotectant mass ratio >2 also showed an 
undesirable cake appearance when the NaCl concentration was 80 mM (e.g. formulations 3 and 
5), thus when high concentrations of NaCl are present, even higher bulking agent/cryoprotectant 
mass ratios (e.g. >10) are needed to guarantee an adequate cake, such as in formulation 13 
(Supplementary Table 2). Lyophilization process optimization could potentially solve this issue 
allowing the use of NaCl in the formulation and a lower bulking agent/cryoprotectant mass 
ratio. Several key process parameters could be optimized to ensure a good cake appearance 
using the excipients above, for instance, the freeze ramp rate, the final temperature of each step, 
chamber pressure and time. However, a simple solution could be to simply reconstitute with a 
NaCl solution. 
Evaluation of NaCl effects by freeze drying microscopy 
Freeze drying microscopy was performed on formulation 6 in the presence and absence of NaCl 
to compare the effect of the salt on critical temperatures of the freeze-drying process, especially 
on the collapse event. This analysis showed a significant difference between the collapse 
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temperature (Tcol) of these 2 conditions as expected. As shown in Figure 2, Tcol was -24.1°C for 
the sample without NaCl, and -35.4°C for the sample with NaCl. Since salts exhibit low Tg¶
values, even low NaCl concentration (<0.2% m/v or 34 mM) can significantly depress the Tg¶ 
values (Passot et al. 2010). When the product temperature exceeds the Tg¶ value during the 
lyophilization process, the rigid glass softens to become a highly viscous rubbery material and 
collapses. 
FIGURE 2 
The effects of different excipients on the stability of Factor IX after lyophilization and 
subsequent storage at different temperatures 
We next investigated removing factors with a negative effect on formulation, for example, the 
NaCl due its influence on Tg¶ decrease and the potential longer term effect on stability. The 
bulking agent/cryoprotectant mass ratio was established as being maintained at a minimum of 2, 
and the histidine and polysorbate 80 concentrations in all new formulations were fixed based on 
literature (Bush et al 1998; Wang 2000). This rationale resulted in 4 new formulations (named 
A-D), which were compared to the Benefix® formulation. All five formulations showed an 
elegant cake appearance, whereas the condition without excipients looked to have collapsed as 
expected (Supplementary Figure 2).  
The average FIX activity prior to lyophilization was 69.1 ± 6.6 IU/ml. The rFIX activity 
measured in formulations A, B, C and D was more-or-less the same upon reconstitution 
immediately after lyophilization, compared with the starting value (Figure 3A). The activity in 
the samples with no excipients decreased dramatically as expected compared with the values 
before lyophilization and all five formulations tested after lyophilization, highlighting the 
importance of a combination of excipients to protect the protein, maintaining stability and 
activity. 
The longer-term stability study at different temperatures (Figure 3B) showed little 
change in Factor IX activity in the different formulations stored at 4°C for 3 months (T90) when 
compared to the respective first time point (T0, Figure 3A). The same was observed for samples 
stored at room temperature, except for formulation B, where storage at room temperature 
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resulted in lower activity. In the samples stored at 40°C (accelerated degradation study) there 
was a large decrease in observed FIX activity. At this higher temperature, results were 
equivalent for samples stored for 45 and 90 days (Figure 3C).  
FIGURE 3 
When the residual water was analyzed in samples over time, only the Benefix formulation 
showed an increase in residual moisture as shown in Figure 4, but not above the levels 
recommended in the literature, e.g. 3%, after 3 months (Passot et al. 2010). The other 
formulations showed no significant change over 3 months. Further analysis for the presence of 
aggregates revealed that samples purified from batch mode CHO cultivation had FIX monomer 
proportions of 95% and that the T0 samples all had monomer proportions of 92.21 to 93.5% 
(Figure 5). This indicates that aggregate formation due to lyophilization was small and that most 
product aggregates found were already present in the samples. The proportion of aggregates was 
substantially higher in samples with no excipients. All four formulations were equivalent to the 
Benefix® formulation in terms of particle size distribution (Supplementary Figure 3) and cake 
appearance (Supplementary Figure 2). Dynamic light scattering indicated that the aggregates 
detected by SEC-HPLC had a heterogeneous size distribution. 
FIGURES 4 AND 5 
Conclusions 
Here we show that formulations B, C and D are suitable for formulating recombinant FIX as 
they give comparable data to that obtained with the formulation of commercially available 
Benefix® using the freeze-drying protocol adapted from Tang and Pikal (2004), when stored at 
2-8°C after lyophilization for at least three months in line with the approved shelf life 
temperature for commercial recombinant FIX according to the EMEA (2005). The use of the 
different excipients and concentrations reported here therefore represent an alternative to the 
commercial Benefix formulation for lyophilization of factor IX. Further, the use of mannitol 
could impact upon the formulation costs since this excipient is cheaper than glycine. 
Furthermore, whilst trehalose is more expensive compared to sucrose, trehalose has a higher Tg¶ 
(consequently increasing the formulation Tg¶making possible the use of higher temperatures 
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during the lyophilization. This would, in turn, enable significant time and cost savings through 
process optimization. Additionally, modification to the protein can occur due to glycation as a 
result of sucrose hydrolysis to yield reducing sugars (Smales et al, 2002), this would not occur 
with trehalose. Vials without excipients, containing solely rFIX protein, showed significant 
activity loss and higher levels of soluble aggregates compared with all 5 formulations 
reinforcing the importance of a combination of excipients to maintain the stability of the 
recombinant FIX product during the freeze-drying process. Formulations B, C and D contain the 
surfactant polysorbate-80, sucrose or trehalose as cryoprotectant, mannitol or glycine as bulking 
agent, L-histidine as buffering agent, and NaCl added in the reconstitution liquid at a 0.234% 
(w/v) concentration. We therefore propose these as alternative formulations for the protection of 
Factor IX during lyophilization and subsequent storage. 
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Figure 1. Cake appearance of samples formulated with Benefix® (top) and Rixubis® (bottom) 
excipients and lyophilized according to the methods adapted from Ronzi et al. (2003) (A and C) 
and from Tang and Pikal (2004) (B and D). 
Figure 2. Freeze-drying microscopy images of sample 6 from the DoE study, with (A) and 
without (B) NaCl. The temperature at which the collapse began to be observed was ± 35.4°C 
and ± 24.1°C, respectively. The annealing conditions used were -10°C for 600 seconds. 
Figure 3. FIX activity chart from formulations A to D and from rFIX formulated with Benefix® 
excipients. (A) represents T0, (B) T90 (4°C, room temperature and 40°C) and (C) T0, T45 and T90 
stored at 40°C. Error bars represent standard deviations (n = 3). 
Figure 4. Residual moisture measured by Karl Fisher titration on formulations A to D and from 
rFIX formulated with Benefix® excipients. (A) represents T0, (B) T90 (stored at 4°C, room 
temperature and 40°C) and (C) T0, T45 and T90 stored at 40°C. 
Figure 5. Monomer (right) and soluble aggregate levels (left) measured by SEC-HPLC from 
formulations A to D and from rFIX formulated with Benefix® excipients analyzed at three time 




Table 1. Components of the four different formulations investigated fora CHO-derived 
rFIX product 




A 40 mM sucrose 350 mM glycine 
12.5 mM L-
histidine 
0.004% (v/v) Polysorbate 
80 










350 mM glycine 
12.5 mM L-
histidine 














Table 2. Lyophilization method adapted from Tang and Pikal (2004) 
















1 25 15 H -40 30 100 H 
2 5 20 R -20 40 100 R 
3 5 30 H -20 1200 100 H 
4 -5 10 R -20 1200 100 H 
5 -5 30 H 25 450 100 R 
6 -40 35 R Secondary Drying 
7 -40 120 H 25 360 100 H 
8 -10 30 R - - - - 
9 -10 120 H - - - - 
10 -40 30 R - - - - 





Table 3. Lyophilization method adapted from Ronzi et al (2003) 
















1 25 15 H -40 30 150 H 
2 5 20 R -30 60 150 R 
3 5 30 H -30 10 150 H 
4 -5 10 R -15 240 150 R 
5 -5 30 H -15 10 150 H 
6 -40 35 R -5 240 150 R 
7 -40 120 H -5 10 150 H 
8 -10 30 R -5 30 120 H 
9 -10 120 H Secondary Drying 
10 -40 30 R 25 600 120 R 




Table 4. Storage times and temperatures before reconstitution and analysis of Factor IX in 
formulations A-D and in Benefix® formulation 
 
Temperature of storage of 
lyophilized samples (ºC) 
Time of storage of 
lyophilized samples 
(days) 
No storage (immediate 
reconstitution and analysis) 
0 
4ºC 90 
Room temperature 90 







Figure 1. Cake appearance of samples formulated with Benefix® (top) and Rixubis® (bottom) 
excipients and lyophilized according to the methods adapted from Ronzi et al. (2003) (A and C) 








Figure 2. Freeze-drying microscopy images of sample 6 from the DoE study, with (A) and 
without (B) NaCl. The temperature at which the collapse began to be observed was ± 35.4°C 








Figure 3. FIX activity chart from formulations A to D and from rFIX formulated with 
Benefix® excipients. (A) represents T0, (B) T90 (4°C, room temperature and 40°C) and 







Figure 4. Residual moisture measured by Karl Fisher titration on formulations A to D 
and from rFIX formulated with Benefix® excipients. (A) represents T0, (B) T90 (stored 







Figure 5. Monomer (right) and soluble aggregate levels (left) measured by SEC-HPLC from 
formulations A to D and from rFIX formulated with Benefix® excipients analyzed at three time 
points: T0 (A), T45 (B) and T90 at 4°C (C), room temperature (D) and 40°C (E). 
 
 27 
Supplementary Table 1. Excipients and concentration ranges used in the Design of 
Experiments (DoE).  
Type Factor Units -1 0 +1 
Numeric 
Cryprotectant concentration mM 14 52 90 
Bulking agent concentration mM 100 200 300 
Buffer concentration mM 5 12.5 20 
Polysorbate-80 concentration % v/v 0.001 0.003 0.005 
NaCl concentration mM 0 40 80 
Categoric 
Cryoprotectant Sucrose Trehalose 
Bulking agent Glycine Mannitol 




Supplementary Table 2. Two-level fractional factorial design of experiment (resolution IV) 
showing the 3 categorical factors and the 5 numeric factors (concentration ranges). The 
responses evaluated were cake appearance and Factor IX activity after reconstitution in 1 ml of 
ultrapure water. Samples were treated in a randomized sequence. Cake appearance was 
























1 Sucrose Mannitol L-histidine 14 5 100 0.001 0 3.80 21.1 0 
2 Sucrose Glycine Na citrate 90 5 100 0.001 80 0.24 22.4 0 
3 Trehalose Mannitol Na citrate 14 20 100 0.001 80 3.80 25.4 0 
4 Trehalose Glycine L-histidine 90 20 100 0.001 0 0.24 24.3 1 
5 Trehalose Glycine L-histidine 14 5 300 0.001 80 4.70 23.1 0 
6 Trehalose Mannitol Na citrate 90 5 300 0.001 0 1.77 22.9 1 
7 Sucrose Glycine Na citrate 14 20 300 0.001 0 4.69 17 1 
8 Sucrose Mannitol L-histidine 90 20 300 0.001 80 1.77 18.2 1 
9 Trehalose Glycine Na citrate 14 5 100 0.005 0 1.56 21.8 0 
10 Trehalose Mannitol L-histidine 90 5 100 0.005 80 0.59 22.7 0 
11 Sucrose Glycine L-histidine 14 20 100 0.005 80 1.57 19.5 0 
12 Sucrose Mannitol Na citrate 90 20 100 0.005 0 0.59 25.8 1 
13 Sucrose Mannitol Na citrate 14 5 300 0.005 80 11.40 17.8 1 
14 Sucrose Glycine L-histidine 90 5 300 0.005 0 0.73 19.8 0 
15 Trehalose Mannitol L-histidine 14 20 300 0.005 0 11.40 22.9 1 
16 Trehalose Glycine Na citrate 90 20 300 0.005 80 0.73 21.4 0 
17 Sucrose Mannitol L-histidine 52 12.5 200 0.003 40 2.05 20.8 1 
18 Trehalose Mannitol L-histidine 52 12.5 200 0.003 40 2.05 19.6 1 
19 Sucrose Glycine L-histidine 52 12.5 200 0.003 40 0.84 14.3 0 
20 Trehalose Glycine L-histidine 52 12.5 200 0.003 40 0.84 19.4 0 
 29 
21 Sucrose Mannitol Na citrate 52 12.5 200 0.003 40 2.05 26.5 1 
22 Trehalose Mannitol Na citrate 52 12.5 200 0.003 40 2.05 20.6 1 
23 Sucrose Glycine Na citrate 52 12.5 200 0.003 40 0.84 20.8 0 
24 Trehalose Glycine Na citrate 52 12.5 200 0.003 40 0.84 22.3 0 
25 Sucrose Mannitol L-histidine 52 12.5 200 0.003 40 2.05 28.1 1 
26 Trehalose Mannitol L-histidine 52 12.5 200 0.003 40 2.05 35.9 1 
27 Sucrose Glycine L-histidine 52 12.5 200 0.003 40 0.84 34.3 0 
28 Trehalose Glycine L-histidine 52 12.5 200 0.003 40 0.84 20.3 0 
29 Sucrose Mannitol Na citrate 52 12.5 200 0.003 40 2.05 26.7 1 
30 Trehalose Mannitol Na citrate 52 12.5 200 0.003 40 2.05 20.3 1 
31 Sucrose Glycine Na citrate 52 12.5 200 0.003 40 0.84 19.3 0 
32 Trehalose Glycine Na citrate 52 12.5 200 0.003 40 0.84 24.6 0 
33 Sucrose Mannitol L-histidine 52 12.5 200 0.003 40 2.05 22 1 
34 Trehalose Mannitol L-histidine 52 12.5 200 0.003 40 2.05 25.5 1 
35 Sucrose Glycine L-histidine 52 12.5 200 0.003 40 0.84 27.1 0 
36 Trehalose Glycine L-histidine 52 12.5 200 0.003 40 0.84 22.7 0 
37 Sucrose Mannitol Na citrate 52 12.5 200 0.003 40 2.05 28.3 1 
38 Trehalose Mannitol Na citrate 52 12.5 200 0.003 40 2.05 25.2 1 
39 Sucrose Glycine Na citrate 52 12.5 200 0.003 40 0.84 22 0 
40 Trehalose Glycine Na citrate 52 12.5 200 0.003 40 0.84 24.7 0 
41 Sucrose Mannitol L-histidine 52 12.5 200 0.003 40 2.05 25.5 1 
42 Trehalose Mannitol L-histidine 52 12.5 200 0.003 40 2.05 23 1 
43 Sucrose Glycine L-histidine 52 12.5 200 0.003 40 0.84 26.2 0 
44 Trehalose Glycine L-histidine 52 12.5 200 0.003 40 0.84 23.7 0 
45 Sucrose Mannitol Na citrate 52 12.5 200 0.003 40 2.05 22.3 1 
46 Trehalose Mannitol Na citrate 52 12.5 200 0.003 40 2.05 22.7 1 
47 Sucrose Glycine Na citrate 52 12.5 200 0.003 40 0.84 22.1 0 






Supplementary Figure 1. DSC thermal analysis of rFIX samples formulated with Benefix® 
(A) and Rixubis® (B) excipients. Both rFIX formulations had an ice nucleation temperature of -






Supplementary Figure 2. Cake appearance after the lyophilisation of formulations A to D, 





Supplementary Figure 3. Particle size profiles (by DLS) of formulations A to D, rFIX 
formulated with Benefix® excipients and the condition with no excipients for all three time 
points analyzed. 
 
 
 
